CAS: 64019-93-8; Dipivefrin Hydrochloride

上下游产品

phenyl>ethan-1-ol(R)-2-(N-benzyl-N-methylamino)-1-3',4'-bis(pivaloyl)oxyphenylethan-1-ol pivaloyl chloride 4-formyl-1,2-phenylene bis(2,2-dimethylpropanoate) phenyl>-2-(p-tolylsulfinyl)ethan-1-on(R)-1-3',4'-bis(pivaloyl)oxyphenyl-2-(p-tolylsulfinyl)ethan-1-on

📜[4-[2-[benzyl(Methyl)Amino]Propanoyl]-2-(2,2-Dimethylpropanoyloxy)Phenyl] 2,2-Dimethylpropanoate 反应生成 盐酸地匹福林
参考文献:Ogata,Kadzumi;Tehrayama,Xideho
标题:Ogata,Kadzumi;Tehrayama,Xideho

专利信息

专利号:US-6723850-B1
优先权日:1998-08-03
标 题 :Process for the synthesis of (1-H)-benzo[c]quinolizin-3-ones derivatives
发明人：GUARNA ANTONIO; SERIO MARIO; OCCHIATO ERNESTO
权利人:APPLIED RESEARCH SYSTEMS
摘要:The present invention refers to a process for the preparation of (1H)-benzo[c]quinolizin-3-ones derivatives of general formula (I) which involves only three steps and the use, as starting products, of commercially available, or easily preparable, compounds. The compounds of formula (I) are useful as inhibitors of 5α-reductases.

专利号:US-10384987-B2
优先权日:2014-12-16
标 题 :1,3-butadiene synthesis
发明人：DREISBACH CLAUS; SCHLENK STEFAN; HOFFMANN MARTINA; LARCHER CHRISTOPH; FOELLINGER THOMAS
权利人:ARLANXEO DEUTSCHLAND GMBH
摘要:The invention relates to a process for preparing 1,3-butadiene by means of ene-yne metathesis over at least one transition metal catalyst of the element ruthenium.

专利号:CN-109280055-A
优先权日:2017-07-20
标 题 :The method of asymmetric synthesis of ergot alkaloid

专利号:CN-104812770-B
优先权日:2012-07-31
标题 :Synthesis of deuterated ribonucleosides, N-protected phosphoramidites and oligonucleotides

专利号:CN-104812770-A
优先权日:2012-07-31
标 题 :Synthesis of deuterated ribonucleosides, N-protected phosphoramidites and oligonucleotides

专利号:US-5512577-A
优先权日:1994-06-02
标 题:Bicyclic hexahydroaporphine and 1-benzyloctahydroisoquinoline therapeutic compositions and processes for utilizing said compositions
发明人：ROCHE VICTORIA F; OHIA S EDET; ROCHE EDWARD B
权利人:UNIV CREIGHTON
摘要:The invention relates to the method of synthesis of bicyclic hexahydroaporphine compounds which may provide improved therapy for diseases characterized by an increase in intraocular pressure. More specifically, the present invention relates to the preparation of agents which may provide for improved treatment of patients with glaucoma or ocular hypertension. The present invention describes the intraocular pressure lowering capabilities of several of the bicyclic hexahydroaporphine structures.